Jefferies analyst Tycho Peterson upgraded GeneDx (WGS) to Buy from Hold with an unchanged price target of $80. After spending time with management, the firm is confident in 30% volume growth for 2025 for GeneDx. It sees a second half of 2025 ramp from NICU and new indications, while further cost reductions offers room for margin expansion. Jefferies finds the stock’s valuation “compelling” after the recent selloff.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on WGS: